Dr. Sartor on Distinguishing Between Symptomatic and Asymptomatic Patients

Video

In Partnership With:

Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses the distinction between symptomatic and asymptomatic patients with bone metastases from prostate cancer.

Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses the distinction between symptomatic and asymptomatic patients with bone metastases from prostate cancer.

The FDA indication for radium-223 states that patients should have symptomatic disease, though Sartor says he is unsure of the true importance of this. As pain tolerance varies, Sartor says, he does not factor it into his decision — he is more likely to consider the burden of bony disease.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD